FDA recall record

Deseo Rebajar Adipotrim XT, New Powerful Formula, 30 rapid release capsules per bottle recall — FDA D-1277-2014

Marketed Without an Approved NDA/ANDA: FDA lab results found undeclared API Fluoxetine in this dietary supplement.

Class Iclassification
D-1277-2014official record ID
May 7, 2014report date

Recall record at a glance

Official recordD-1277-2014
CategoryDrug Recalls
ClassificationClass I
FDA record statusTerminated
Recalling firmDeseo Rebajar
Report dateMay 7, 2014
Recall initiation dateNov 7, 2013
Quantity1,146 bottles
LocationFajardo, PR, United States

Official product description

Adipotrim XT, New Powerful Formula, 30 rapid release capsules per bottle, Dietary Supplement, www.adipotrim.com.

Why the product was recalled

Marketed Without an Approved NDA/ANDA: FDA lab results found undeclared API Fluoxetine in this dietary supplement.

Distribution information

Nationwide and Puerto Rico

How to read the classification

FDA Class I indicates a situation in which there is a reasonable probability that use of or exposure to the product will cause serious adverse health consequences or death. The classification shown here comes directly from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.